Vn96 synthetic peptide
The Vn96 Synthetic Peptide for EV capture

The proprietary Vn96 technology (US Patent # 8,956,878, EU Patent # 2688904) is a highly effective and flexible tool for the isolation and purification of extracellular vesicles (EV) that aims at improving and accelerating molecular diagnostics based on biofluid analysis.
VIEW VN96 technical PUBLICATION





What are exosomes and EVs?

Exosomes and extracellular vesicles (EVs) are cell-derived nano-sized membrane-encapsulated particles (30-300nm) that act as intermediates in an elaborate communication network, which cells in the body use to deliver complex messages to other cells. EVs can be viewed as nano-cargo transports that circulate in both humans and animals and contain vital information that can inform us in real-time on both normal and disease processes that are occurring within the body. As such, EVs contain a sample of the DNA, RNA, protein and metabolites found within the cells from which they are derived. Since EVs appear in body fluids such as blood and urine, they are also a biomarker source that may be obtained by minimally-invasive methods in order to screen for disease.

Exosomes

Vn96 Synthetic Peptide

The Vn96 peptide has a high specificity and affinity for canonical heat shock proteins (HSPs) lining the surface of exosomes and other extracellular vesicles (EVs). The ease with which the EVs may be captured from cell culture media and biological fluids using the peptide is unprecedented. This technology is a more efficient isolation method than current methods based on physical characteristics (density and/or size separations) and multiple antibody affinity-based purifications.

Due to their high content in HSPs, the peptide can isolate EVs derived from cells under stress (ex: cancer, infection, cardiovascular, neurodegenerative and metabolic diseases) in human or animal body fluids. These EVs can then be analysed for their content in specific pathological biomarkers. This method follows the current clinical diagnostic trend for biomarker screening with non-invasive or minimally invasive measures intended for early disease detection.

Vn96 is a cutting-edge platform technology for enhancing and improving the efficacy, specificity and rapidity of a wide array of disease diagnostic, prevention and treatment technologies. Given its peptide nature and possible chemistries, Vn96 is cost effective, highly flexible and adaptable to your products.

For technology information, collaborations or partnerships, please contact: 

Remi Richard
Business Development Agent
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone : +1 506 869 2048
Fax : +1 506 862 7571

Twitter

Archived Articles

btn campain EN
Atlantic Cancer Research Institute 
Pavillon Hôtel-Dieu
35, Providence Street
Moncton, NB E1C 8X3 Canada

info@canceratl.ca
Tel.: 506-862-7512
Fax.: 506-862-7571

Annual Report 2017 Cover
Our annual report
Download PDF bullet blanc

The Atlantic Cancer Research Institute

 (ACRI) is a non-profit organization founded in late 1998 and housed at the Dr. Georges-L.-Dumont University Hospital Centre in Moncton. Thanks to its unique expertise, ACRI has become a true centre of excellence in cancer research.

Our Partners

logo excipio logo chudumont logo soricimedlogo neplogo ccslogo umonctonlogo unblogo vitalitelogo conceptiaCRS logoNBHRF logoMerck Logo.svg